Swaminathan Iyer, MD
Hematology · Houston, TXNPI 1063493229
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $40,013 of the $50,294 with a category attached, or 79.6%. 16 manufacturers reported payments, led by Acrotech Biopharma Inc. at 44.8% of the total. Among hematology clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 67 payments — averaging $750.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Acrotech Biopharma Inc.$23K
- Seagen Inc.$11K
- Pfizer$5K
- Sanofi$5K
- Daiichi Sankyo Inc.$4K
- AstraZeneca$546
- plus $2K from 10 others
Across 231 payments — averaging $43,830 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Seagen Inc.$5.4M
- Merck$3.2M
- Trillium Therapeutics USA, LLC$875K
- Astrazeneca UK Limited$348K
- Pfizer$183K
- Aurobindo Pharma USA, Inc.$115K
- plus $33K from 6 others
What the payments were for
- Consulting fees$40,01380%
- Speaking & faculty fees$6,48013%
- Travel & lodging$1,8204%
- Food & beverage$1,9814%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Acrotech Biopharma Inc. | 24 | $22,555 |
| Seagen Inc. | 15 | $11,347 |
| Pfizer | 6 | $5,414 |
| Sanofi | 1 | $4,732 |
| Daiichi Sankyo Inc. | 7 | $3,865 |
| AstraZeneca | 1 | $546 |
| Vertex | 1 | $475 |
| Beigene, Ltd. | 1 | $450 |
| Kyowa Kirin, Inc. | 3 | $328 |
| Rigel Pharmaceuticals, Inc. | 2 | $178 |
| ADC Therapeutics America, Inc. | 1 | $151 |
| Stemline Therapeutics Inc. | 1 | $133 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $38 |
| Genentech, Inc. | 1 | $35 |
| Gilead | 1 | $27 |
| Novartis | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$50,294 in reported general payments places this provider in the 90th percentile of 97 hematology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lenalidomide | 20 | $261,648 |
| RevlimidLenalidomide | 17 | $235,041 |
| ValacyclovirValacyclovir Hcl | 53 | $1,140 |
| Pantoprazole Sodium | 14 | $109 |
| Ondansetron Hcl | 16 | $98 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 41 | $70 |
| Prednisone | 16 | $24 |
Paid to pharmacies, not to this prescriber.
Other hematology in Houston
- Miguel EscobarHouston$767K
- Kelty BakerHouston$229K
- Siddhartha GangulyHouston$119K
- Lawrence RiceHouston$103K
- Modupe IdowuHouston$102K
- Jing YeHouston$34K
- Senthil SukumarHouston$31K
- Sa WangHouston$27K
- Uday PopatHouston$25K
- Rashmi Kanagal ShamannaHouston$20K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.